© 2022 MJH Life Sciences™ and Contemporary OB/GYN. All rights reserved.
Breast Cancer
Premenopausal ER+ breast cancer recurrence reduced significantly with aromatase inhibitors
December 22, 2021
Compared with tamoxifen, aromatase inhibitors were revealed to be more effective in reducing the rate of recurrence in ER+ breast cancer among premenopausal women receiving ovarian suppression.
Using a biomarker-driven approach in TNBC
December 21, 2021
In using the biomarker approach to the treatment of triple-negative breast cancer, the challenge for the clinician is prioritizing the available treatment options based on the National Comprehensive Cancer Network guidelines for breast cancer, which focus on active agents, preferred single-agent chemotherapy approaches, and doublet options for certain patients at high risk.
Certain postmenopausal patients with breast cancer can avoid chemotherapy, study shows
December 13, 2021
Certain post-menopausal women with HR-positive, HER2-negative breast cancer may be able to only undergo endocrine therapy after surgery – sparing themselves from the chemotherapy side effects.
Study confirms adding palbociclib to endocrine therapy may not improve outcomes in early breast cancer
December 10, 2021
The addition of palbociclib to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.
Novel drug has potential to ‘become new standard of care’ in advanced, ER-positive breast cancer
December 10, 2021
The study results — which were presented during the 2021 San Antonio Breast Cancer Symposium — indicated that elacestrant, a selective estrogen receptor degrader (SERD), led to a 30% reduction in the risk of disease progression or death compared with standard of care in the study population.
FDA grants olaparib priority review in BRCA-mutated HER2-negative high-risk early breast cancer
December 01, 2021
Olaparib, which was granted priority review by the FDA, has been shown to improve invasive disease-free survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.
Racial disparities in surgical management of breast cancer among Native American and Native Alaskan patients
November 12, 2021
Findings from a study indicated that non-Hispanic American Indian and Alaskan Native patients with breast cancer were more likely to undergo a mastectomy compared with non-Hispanic White patients.
Same mutations linked to breast cancer risk found in black, white women
November 08, 2021
A recently published study evaluated nearly 30,000 patients and found about 5% of Black and White women have the same genetic mutations that are associated with an increased risk of breast cancer.
Lack of health insurance directly reduces cancer screening rates, most recent and long-term
November 08, 2021
Disparities across the globe continue to surface as we approach year 2 of the COVID-19 pandemic, especially in health care. As one considers its implications, a research team from the American Cancer Society investigated its potential impact on early cancer detection.
New study shows racial disparities in genetic testing referrals for women
November 05, 2021
A recent study suggests that unconscious or implicit bias may exist when it comes to physicians referring African American patients with breast cancer for genetic counseling and testing.